A new generation of diagnostic systems for a wide range of socially important diseases is being developed in the Nanomedicine Group of LNBE, MEPhI

Highly sensitive methods for simultaneous detection of various biomarkers constitute the basis for early diagnosis of all known diseases.

A new generation of these methods employs nanosized fluorescent probes. They consist of semiconductor particles with attached antibodies recognizing biomarkers of diseases on the surface of altered (e.g., tumor) cells, thereby differentiating them from normal, "healthy" cells.

The use of these probes not only improves the quality and accuracy of clinical analysis of oncological, infectious, immune, and other diseases, but also ensures their earliest possible diagnosis, which, in turn, determines the efficacy of the subsequent treatment.

Researchers of the Nanomedicine Group of LNBE in collaboration with the European Technological Platform "Semiconductor Nanocrystals" have developed a unique technology for binding nanocrystals with so-called single-domain antibodies.

The advantages of nanocrystals include their unique photostability and small size, as well as the possibility to excite fluorescence of different colors (the color depending on the nanocrystal composition and size) with light of the same wavelength (a lamp or a laser is used as a source). This allows a researcher to easily locate probes of different types in a body or tissue specimen.

Single-domain antibodies are produced by lymphocytes of llamas, camels, and sharks. They differ from antibodies of other animals in their simpler structure and correspondingly smaller size. For example, llama antibodies are 12 times smaller than "full-size" antibodies of most other mammals, including humans. As a result, the total size of the probe is also considerably smaller compared to probes that contain "traditional" antibodies. This is important because these probes better cross blood–tissue barriers, penetrate deeper into the tissue, and, hence, reach their target cells more easily, which increases the accuracy and reliability of diagnosis.

All this makes diagnostic probes based on nanocrystal–single-domain-antibody conjugates developed in the Nanomedicine Group unprecedentedly small, specific, and sensitive nanoprobes for detection of disease biomarkers in tissue sections and in the human body (in vivo).

The ultrasensitive nanoprobes developed in the Nanomedicine Group serve as the basis for multimodal systems for ultra-early diagnosis of infectious, autoimmune, and oncological diseases.

Contact:

Alyona V. Sukhanova, M.D., Ph.D., current address: University of Reims Champagne-Ardenne, France, alyona.sukhanova@univ-reims.fr

 

Publications on the subject from the Nanomedicine Group of LNBE:

Sukhanova, A., Even-Desrumeaux, K., Chames, P., Baty, D., Artemyev, M., Oleinikov, V., Nabiev, I. (2012) Engineering of ultra-small diagnostic nanoprobes through oriented conjugation of single-domain antibodies and quantum dots. Nature Protocols Exchange, DOI: http://dx.doi.org/10.1038/protex.2012.042;

Sukhanova, A., Even-Desrumeaux, K., Millot, J., Chames, P., Baty, D., Artemyev, M., Oleinikov, V., Cohen, J., Nabiev, I. (2012) Oriented conjugates of monoclonal and single-domain antibodies with quantum dots for flow cytometry and immunohistochemistry diagnostic applications, in Colloidal Nanocrystals for Biomedical Applications, eds. W.J. Parak, Kenji Yamamoto, Marek Osinski, Proceedings of SPIE Vol. 8232 (SPIE, Bellingham, WA 2012) 82320T.

http://proceedings.spiedigitallibrary.org/proceeding.aspx?articleid=1276788

Sukhanova, A., Even-Desrumeaux, K., Kisserli, A., Tabary, T., Reveil, B., Millot, J.M., Chames, P., Baty, D., Artemyev, M., Poly, S., Oleinikov, V.A., Pluot, M., Cohen, J., Nabiev, I. (2012) Oriented conjugates single-domain antibodies and quantum dots: Toward new generation of ultra-small diagnostic nanoprobes. NanoMedicine: NBM, 8, 516-525.

http://www.sciencedirect.com/science/article/pii/S154996341100284X

 
 
 
© 2012 Laboratory of Nano-BioEngineering